Patient-Centered Standards for Medically Integrated Dispensing: ASCO/NCODA Standards.

Purpose: To provide standards for medically integrated dispensing of oral anticancer drugs and supportive care medications.

Methods: An Expert Panel was formed, and a systematic review of the literature on patient-centered best practices for the delivery of oral anticancer and supportive care drugs was performed to April 2019 using PubMed and Google Scholar. Available patient-centered standards, including one previously developed by the National Community Oncology Dispensing Association (NCODA), were considered for endorsement.

Recent advances in antiemetics: new formulations of 5HT-receptor antagonists.

Purpose: To discuss new therapeutic strategies for chemotherapy-induced nausea and vomiting (CINV) involving 5-hydroxytryptamine type 3 (5HT)-receptor antagonists (RAs).

Summary: CINV remains poorly controlled in patients receiving moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC); nausea and delayed-phase CINV (24-120 hours after chemotherapy) are the most difficult to control. National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) antiemesis-guideline recommendations for HEC include a four-drug regimen (5HT RA, neurokinin 1 [NK] RA, dexamethasone, and olanzapine).